LifeSci Acquisition Corp.
Status: Deal Closed
U=S+W
W=S/2@11.5
| IPO Proceeds, $M | $65.64M |
|---|---|
| IPO Date | Mar 6, 2020 |
| CEO | Andrew McDonald, Ph.D. |
| Left Lead | Chardan |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Healthcare in North America |
| IPO Geography | US/Canada |
| Target Company | Vincera Pharma |
| Deal Announced | Sep 29, 2020 |
| Deal Size, $M | $77.05M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Dec 22, 2020 |
| Amendment Vote | TBD |
| Closing Date | Dec 23, 2020 |
Formerly LSAC
VINC
VINCW
| Price | $0.27 |
|---|---|
| Last closing price | $0.29 |
| H/L, 52-week | $0.63 / $1.95 |
| Volume, today | 252,031 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on LifeSci Acquisition Corp.:
- Structure and cap table
- 9 directors & officers
- 21 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Andrew McDonald, Ph.D. | 46 | Chairman and CEO |
| Michael Rice | 55 | COO |
| David Dobkin | 40 | CFO |
| Jonas Grossman | 45 | Director |
| Karin Walker | 56 | Director |
| Barry Dennis | 55 | Director |
| John Ziegler, M.D. | 61 | Director |
| Brian Schwartz, M.D. | Director | |
| Adam Tomasi, Ph.D. | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Chardan | BR | 6,000,000 | units |
| B. Riley FBR | 1 | ||
| 6,000,001 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.